Skip to main content
Skip to content
Case File
d-24448House OversightOther

Bob Hugin’s Celgene background highlighted in campaign materials

The passage merely outlines Hugin’s career at Celgene and his political candidacy, with no specific allegations, financial transactions, or novel connections to misconduct. It provides background cont Bob Hugin was CEO and later executive chairman of Celgene before running for U.S. Senate in New Jers Celgene’s flagship drug Revlimid generated $8.2 billion in 2017 sales. Hugin’s campaign references

Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #028415
Pages
2
Persons
1
Integrity
No Hash Available

Summary

The passage merely outlines Hugin’s career at Celgene and his political candidacy, with no specific allegations, financial transactions, or novel connections to misconduct. It provides background cont Bob Hugin was CEO and later executive chairman of Celgene before running for U.S. Senate in New Jers Celgene’s flagship drug Revlimid generated $8.2 billion in 2017 sales. Hugin’s campaign references

Tags

pharmaceuticalspolitical-backgroundnew-jerseypoliticsbob-hugincelgenefinancial-performancehouse-oversightcampaign

Ask AI About This Document

0Share
PostReddit

Extracted Text (OCR)

EFTA Disclosure
Text extracted via OCR from the original document. May contain errors from the scanning process.
2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are Representative Leonard Lance of New Jersey and former Gov. Chris Christie. Mel Evans/Associated Press"},"identifier":"100000006098011 Sba8b80411187", "imageIdentifier":"el26e7bde26613f 50f2609cb8776d827", "layout": "fullbleed- image", "role":"photo", "type":"scalable image"}, {"identifier":" anf-caption- 1","inlineTextStyles": [{"range":{"length":27, "start ":261},"textStyle":"photo- credit"}],"layout":"default-caption", "role": "caption", "text":"Bob Hugin spoke in 2014 at a groundbreaking ceremony in Summit, N.J., for Celgene, the pharmaceutical company he led until stepping down to run for United States Senate. To his right are Representative Leonard Lance of New Jersey and former Gov. Chris Christie. Mel Evans/Associated Press ","type™:"text"}],"identifier":" anf-container- 5","layout"™:"image- container", "role":"container", "type": "container"}],"identifier":" anf-section- 2","layout":"default- section", "role":"section", "scene": {"fadeColor":"#FFFFFF","type":"fading sticky header"} ,"type™:"section"}, {"additions": [{"URL":"https://www.businesswire.com/news/home/2018012 9005762/en/Celgene-Announces-Retirement-Executive-Chairman-Bob- Hugin", "range": {"length":34, "start ":194},"type":"link"}],"identifier":" anf-body- 6", "inlineTextStyles":[{"range": {"length":363,"start":0},"textstyle":" anf-ts- I"}, {"range"™: {"length":363,"start":0},"textStyle":"_anf-ts-1"}],"layout":"default— body", "role":"body", "text":"When Bob Hugin joined Celgene in 1999 as its chief financial officer, the company was a struggling biotech that sold just one product ae" a leprosy drug 4€" and faced a shaky future. By the time he stepped down as executive chairman in February to run for United States Senate, Celgene had become a pharmaceutical powerhouse with a market value of nearly $80 billion.","type":"text"}, {"additions": [{"URL":"https://ir.celgene.com/press- releases/press-release-details/2018/Celgene-Reports-Fourth-Quarter-and-Full-Year-2017 Operating-and-Financial- Results/default.aspx", "range": {"length":17, "start ":177},"type™:"Link"}],"identifier™:" anf-body-7","inlineTextStyles": [{"range"™: {"length":195,"start":0},"textStyle":" anf-ts- i"}, {"range™: {"length":195,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role":"body", "text":"And that onetime leprosy drug? It had been transformed into Revlimid, a best-selling cancer drug that, with annual sales of $8.2 billion, made up nearly two-thirds of Celgened€™s net sales in 2017.","type™:"text"}, {"additions"™: [{"URL":"https://youtu.be/K4Agl kLfs5w", "range": {"len gth":34,"start":174},"type"™:"link"}],"identifier":" anf-body- 8", "inlineTextstyles": [{"range"<:{"length":324,"start":0},"textstyle":" anf-ts-— I"}, {"range™: {"length":324,"start":0},"textStyle":" anf-ts-1"}],"layout":"default— body", "role": "body", "text":"Mr. Hugin, a Republican mounting a surprisingly strong challenge to Senator Robert Menendez in New Jersey, has made his career at Celgene a cornerstone of his campaign, with television advertisements boasting that he d€cechose a life of serviced€ in the Marines and a€eleading a health care company that develops cancer medicine.a€", "type": "text"}, {"identifier":" anf-body- 9","inlineTextStyles":[{"range": {"length":299,"start":0},"textsStyle":" anf-ts- i"},{"range™: {"length":299,"start":0},"textStyle":" anf-ts-1"}],"layout":"default- body", "role": "body", "text":"In deeply blue New Jersey, few expected a real contest for Mr. Menendezad€™s seat. Yet anger stemming from Mr. Menendeza€™s federal corruption trial last year 4€" a trial that Mr. Hugind這s campaign reminds television viewers in New Jersey about on a regular basis a4€" has dampened his popularity among voters.","type":"text"}, {"bannerType"™: "any", "identifier":" anf-banner advertisement i", "layout": "ComponentLayout-— 4","role":"banner advertisement", "type":"banner advertisement"}, {"additions": [{"URL™:"h ttps://twitter.com/realDonaldTrump/status/1016368503723577344", "range": {"length":21,"st art ™:213}, "type™:"link"}, {"URL":"https://news.gallup.com/poll1/12748/business-industry- sector- ratings.aspx", "range": {"length":16, "start ":238},"type"™:"link"}],"identifier":" anf- body-10", "inlineTextStyles": [{"range"™: {"length":413,"start":0},"textStyle":" anf-ts- I"}, {"range"™: {"length":413,"start":0},"textStyle":" anf-ts-1"}],"layout":"default— body", "role": "body", "text": "But Mr. Hugind€™s professional career could also prove to be a liability da4€" he is the sole pharmaceutical executive running for statewide office in 2018. Anger over high drug prices has risen and President Trump has vilified the industry. A 2017 Gallup poll found that just 33 percent of the country had a favorable view of the drug industry, the second-lowest of any sector. (The lowest was the federal government.)","type":"text"}, {"identifier":" anf-body- 11i","inlineTextStyles": [{"range":{"length":394,"start":0},"textStyle":" anf-ts-

Technical Artifacts (8)

View in Artifacts Browser

Email addresses, URLs, phone numbers, and other technical indicators extracted from this document.

Domaintwitter.com
Phone3723577344
Phone6098011
Phone9005762
URLhttps://ir.celgene.com/press
URLhttps://news.gallup.com/poll1/12748/business-industry
URLhttps://www.businesswire.com/news/home/2018012
URLhttps://youtu.be/K4Agl

Related Documents (6)

DOJ Data Set 9OtherUnknown

From: jeffrey epstein <[email protected]>

29p
House OversightOtherNov 11, 2025

Senate committee chair and ranking member lineup and potential reassignments

The passage lists current and potential future Senate committee leadership positions, but provides no concrete allegations, financial flows, or misconduct. It offers limited investigative value beyond Chairman Lisa Murkowski and Ranking Member Maria Cantwell on an unnamed committee Potential reshuffling of ranking member positions for EPW, Foreign Relations, and Appropriations Senator Jim Inhofe r

1p
DOJ Data Set 9OtherUnknown

DEPARTMENT OF THE TREASURY

9p
DOJ Data Set 11OtherUnknown

EFTA02722137

44p
House OversightUnknown

Celgene Settlement and New Jersey Senate Race Links to Senator Menendez

Celgene Settlement and New Jersey Senate Race Links to Senator Menendez The document references a $280 million Celgene fraud settlement and connects former pharma executive Bob Hugin, a Senate candidate, with Senator Robert Menendez. While the text is largely metadata and lacks concrete transaction details, it hints at possible political‑financial ties that merit follow‑up, especially given Menendez's recent legal scrutiny. The lead is moderately useful but not novel, as Menendez's connections to pharma have been reported before. Key insights: Celgene agreed to pay $280 M to settle fraud claims over cancer drugs (July 2017).; Bob Hugin, a former pharmaceutical executive, ran for U.S. Senate in New Jersey (Feb 2018).; Multiple New York Times articles are linked that discuss Hugin and Menendez’s Senate race.

1p
DOJ Data Set 9OtherUnknown

From: Office of Terje Rod-Larsen

28p

Forum Discussions

This document was digitized, indexed, and cross-referenced with 1,400+ persons in the Epstein files. 100% free, ad-free, and independent.

Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.